局限期小细胞肺癌胸部放射治疗的研究进展

doi:10.13481/j.1671-587x.20180138

摘要/Abstract

摘要： 小细胞肺癌（SCLC）对放化疗敏感，初治缓解率高，但容易复发转移，预后差。局限期小细胞肺癌（LD-SCLC）的标准治疗方案是化疗联合胸部放疗，但目前针对放疗的具体实施模式尚无定论，存在诸多争议。本文作者系统地总结了LD-SCLC胸部放疗的最新研究进展，从放疗介入的时机、靶区勾画范围、放疗剂量和分割方式等方面进行归纳总结，指出同步放化疗优于序贯放疗、早放疗优于晚放疗等共识，提出累及野照射、常规分割高剂量放疗和低分割放疗等未来研究方向。

关键词: 癌, 小细胞, 胸部, 肺, 放射治疗

中图分类号:

R734.2

许昌根, 刘百龙, 龚守良, 刘敏, 董丽华. 局限期小细胞肺癌胸部放射治疗的研究进展[J]. 吉林大学学报(医学版), 2018, 44(01): 190-194.

参考文献

[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J]. J Clin Oncol,2006,24(28):4539-4544.
[2] Byers LA,Rudin CM.Small cell lung cancer:where do we go from here[J].Cancer,2015,121(5):664-672.
[3] Micke P,Faldum A,Metz T,et al.Staging small cell lung cancer:Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease[J].Lung Cancer,2002,37(3):271-276.
[4] Shepherd FA,Crowley J,Van Houtte P,et al.The International Association for the Study of Lung Cancer lung cancer staging project:proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor,node,metastasis classification for lung cancer[J].J Thorac Oncol,2007,2(12):1067-1077.
[5] Ignatius Ou SH,Zell JA.The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition[J].J Thorac Oncol,2009,4(3):300-310.
[6] Vallières E,Shepherd FA,Crowley J,et al.The IASLC Lung Cancer Staging Project:proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer[J].J Thorac Oncol,2009,4(9):1049-1059.
[7] Goldstraw P,Crowley J,Chansky K,et al.The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J].J Thorac Oncol,2007,2(8):706-714.
[8] Almquist D,Mosalpuria K,Ganti AK,et al.Multimodality therapy for limited-stage small-cell lung cancer[J].J Oncol Pract,2016,12(2):111-117.
[9] Verma V,Simone CB,Zhen W.Stereotactic radiotherapy for stage Ⅰ small cell lung cancer[J].Oncologist,2016,21(2):131-133.
[10] Alvarado-Luna G,Morales-Espinosa D.Treatment for small cell lung cancer,where are we now?-a review[J].Transl Lung Cancer Res,2016,5(1):26-38.
[11] Turrisi AT,Kim K,Blum R,et al.Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J].N Engl J Med,1999,340(4):265-271.
[12] El Sharouni SY,Kal HB,Barten-Van Rijbroek A,et al.Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer:a retrospective comparative study[J].Anticancer Res,2009,29(12):5219-5224.
[13] Pignon JP,Arriagada R,Ihde DC,et al.A meta-analysis of thoracic radiotherapy for small-cell lung cancer[J].N Engl J Med,1992,327(23):1618-1624.
[14] Warde P,Payne D.Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis[J].J Clin Oncol,1992,10(6):890-895.
[15] Pijls-Johannesma M,De Ruysscher D,Vansteenkiste J,et al.Timing of chest radiotherapy in patients with limited stage small cell lung cancer:a systematic review and meta-analysis of randomised controlled trials[J].Cancer Treat Rev,2007,33(5):461-473.
[16] De Ruysscher D,Pijls-Johannesma M,Bentzen SM,et al.Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer[J].J Clin Oncol,2006,24(7):1057-1063.
[17] Murray N,Coy P,Pater JL,et al.Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer.The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1993,11(2):336-344.
[18] De Ruysscher D,Lueza B,Le Péchoux C,et al.Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J].Ann Oncol,2016,27(10):1818-1828.
[19] Lueza B,LePéchoux C,Pignon JP,et al.Phase Ⅲ trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer[J].Ann Oncol,2014,25(9):1865-1866.
[20] 刘维帅,赵路军,关勇,等.局限期小细胞肺癌诱导化疗疗效与放疗时机的关系探讨[J].中国肿瘤临床,2014,41(1):73-77.
[21] De Ruysscher D,Bremer RH,Koppe F,et al.Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer:a phase Ⅱ trial[J].Radiother Oncol,2006,80(3):307-312.
[22] Baas P,Belderbos JS,Senan S,et al.Concurrent chemotherapy (carboplatin,paclitaxel,etoposide) and involved-field radiotherapy in limited stage small cell lung cancer:a Dutch multicenter phase Ⅱ study[J].Br J Cancer,2006,94(5):625-630.
[23] Hu X,Bao Y,Zhang L,et al.Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer:interim analysis of a prospective randomized noninferiority trial[J].Cancer,2012,118(1):278-287.
[24] Xia B,Chen GY,Cai XW,et al.Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer[J]. Radiother Oncol,2012,102(2):258-262.
[25] Faivre-Finn C,Snee M,Ashcroft L,et al.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label,phase 3,randomised,superiority trial[J].Lancet Oncol,2017,18(8):1116-1125.
[26] Ulger S,Demirci NY,Aydinkarahaliloglu E,et al.PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancer[J].J Thorac Dis,2015,7(3):295-302.
[27] Cai S,Shi A,Yu R,et al.Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy[J].Radiat Oncol,2014,9:17.
[28] Zhu L,Zhang S,Xu X,et al.Increased biological effective dose of radiation correlates with prolonged survival of patients with limited-stage small cell lung cancer:A systematic review[J].PLoS One,2016,11(5):e0156494.
[29] Xia B,Chen GY,Cai XW,et al.The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer[J].Radiat Oncol,2011,6:50.
[30] Zahra A,Chang T,Hejleh TA,et al.Once daily high-dose radiation (≥ 60 Gy) treatment in limited stage small cell lung cancer[J].J Oncol Transl Res,2016,2(1).pii:108.
[31] Salama JK,Hodgson L,Pang H,et al.A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy:CALGB 30904[J].J Thorac Oncol,2013,8(8):1043-1049.
[32] Lee KJ,Lee EJ,Hur GY,et al.The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer[J].Korean J Intern Med,2013,28(4):449-455.
[33] Sas-Korczynska B,Sokolowski A,Korzeniowski S.The influence of time of radio-chemotherapy and other therapeutic factors on treatment results in patients with limited disease small cell lung cancer[J].Lung Cancer,2013,79(1):14-19.
[34] Xia B,Hong LZ,Cai XW,et al.Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2015,91(3):517-523.
[35] Yee D,Hanson J,Butts C,et al.Phase Ⅰ dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung[J].Radiother Oncol,2010,96(1):78-83.
[36] Murray N,Coy P,Pater JL,et al.Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer.The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1993,11(2):336-344.
[37] Giuliani ME,Lindsay PE,Sun A,et al.Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma[J].Radiother Oncol,2012,102(2):263-267.
[38] Zhang J,Fan M,Liu D,et al.Hypo-or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer[J].Radiat Oncol,2017,12(1):51.
[39] Videtic GM,Stephans KL.The role of stereotactic body radiotherapy in the management of non-small cell lung cancer:an emerging standard for the medically inoperable patient[J]. Curr Oncol Rep,2010,12(4):235-241.
[40] Shioyama Y,Nakamura K,Sasaki T,et al.Clinical results of stereotactic body radiotherapy for Stage Ⅰ small-cell lung cancer:a single institutional experience[J].J Radiat Res,2013,54(1):108-112.
[41] Videtic GM,Stephans KL,Woody NM,et al.Stereotactic body radiation therapy-based treatment model for stage Ⅰ medically inoperable small cell lung cancer[J].Pract Radiat Oncol,2013,3(4):301-306.
[42] Li C,Xiong Y,Zhou Z,et al.Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer:a single-center prospective phase Ⅱ study[J].Med Oncol,2014,31(12):369.
[43] 丁新民,冯华松,伏婷婷,等.紫杉醇顺铂方案联合同步放疗治疗顺铂依托泊苷化疗不敏感局限期小细胞肺癌的临床疗效[J].中国老年学杂志,2016,36(1):344-346.